Dr. Matthew Mezger
77 Cadillac Drive
Sacramento, CA 85827
Ph: 916-929-8564
Fax: 916-929-4529
Send an Email to: Dr. Mezger
Sacramento, CA 85827
Ph: 916-929-8564
Fax: 916-929-4529
Education:
Carroll College, Helena, Montana B.A in Biology- 1975
University of California, Davis M.D- 1980
UC San Francisco/Fresno Valley Medical Center Internal Medicine Residency July 1980- June 1983
UC San Diego Nephrology Fellowship July 1983 - June 1985
University of California, Davis M.D- 1980
UC San Francisco/Fresno Valley Medical Center Internal Medicine Residency July 1980- June 1983
UC San Diego Nephrology Fellowship July 1983 - June 1985
Clinical Appointments:
Kaiser Permanente Medical Center Sacramento, Ca Staff Physician Sept 1985-May 1987
Sutter Community Hospitals Staff Physician
Mercy Community Hospitals Staff Physician
Woodland Memorial Hospital Staff Physician
Marshall Hospital, Placerville Staff Physician
Capital Nephrology Medical Group Sacramento, Ca May 1987- Present Private Practice
Medical Director / Two DaVita Sites
Alhambra Dialysis
1315 Alhambra Blvd #100
Sacramento, CA 95816
Antelope Dialysis
6406 Tupelo Drive #A
Citrus Heights, CA 95621
Sutter Community Hospitals Staff Physician
Mercy Community Hospitals Staff Physician
Woodland Memorial Hospital Staff Physician
Marshall Hospital, Placerville Staff Physician
Capital Nephrology Medical Group Sacramento, Ca May 1987- Present Private Practice
Medical Director / Two DaVita Sites
Alhambra Dialysis
1315 Alhambra Blvd #100
Sacramento, CA 95816
Antelope Dialysis
6406 Tupelo Drive #A
Citrus Heights, CA 95621
Certifications:
American Board of Internal Medicine September 1983
Board Certified in Nephrology, ABIM 1986
American Board of Critical Care 1989
Board Certified in Nephrology, ABIM 1986
American Board of Critical Care 1989
Publications:
Kidney International, Vol. 37, pp 995- 964, 1990 "Chromogranin A in Uremia: Progressive retention in immunoreactive Fragments.
Industry Sponsored Research:
A Randomized, Double-Blind, Parallel group, Placebo-Controlled, Multi- Center Trial, Evaluating the Efficacy and Safety of XXX in Adult Patients on Chronic Hemodialysis.
Selected Clinical Trials:
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Multi-Center Trial Evaluating the Efficacy and Safety of XXX in Adult Patients on Chronic Haemodialysis.
A Phase III , Randomized, Active-Controlled, Open-label, Multi-Center Study of the Safety and Efficacy of XXX Injection for the Maintenance Treatment of Anemia in Haemodialysis Patients previously treated with Epogen.
A Phase-IV, Long Term, Observational Safety Study in End Stage Renal Disease Subjects Treated with XXX.
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, to Evaluate the Safety and Efficacy Of XXX in Patients with Nephropathy Due to Type 2 Diabetes.
Patient Focus Group for Qualitative Assessment of Anemia Associated with Chronic Kidney Disease.
A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of XXX in Patients with Type 2 Diabetes Mellitus and End-Stage Renal Disease who are on Dialysis and who have Inadequate Glycemic Control.
A Phase II Study of the Satety and Efficacy of XXX Injection for the Maintenance Treatment of Anemia in Subjects with Chronic Renal Failure on Haemodialysis, or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.
A Phase III , Randomized, Active-Controlled, Open-label, Multi-Center Study of the Safety and Efficacy of XXX Injection for the Maintenance Treatment of Anemia in Haemodialysis Patients previously treated with Epogen.
A Phase-IV, Long Term, Observational Safety Study in End Stage Renal Disease Subjects Treated with XXX.
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, to Evaluate the Safety and Efficacy Of XXX in Patients with Nephropathy Due to Type 2 Diabetes.
Patient Focus Group for Qualitative Assessment of Anemia Associated with Chronic Kidney Disease.
A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of XXX in Patients with Type 2 Diabetes Mellitus and End-Stage Renal Disease who are on Dialysis and who have Inadequate Glycemic Control.
A Phase II Study of the Satety and Efficacy of XXX Injection for the Maintenance Treatment of Anemia in Subjects with Chronic Renal Failure on Haemodialysis, or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.